Safe Deprescribing Strategies in Patients with Multimorbidity

Abstract

Deprescribing is an essential, evidence-based process in the management of patients with multimorbidity, aiming to optimize pharmacotherapy by reducing polypharmacy and its associated risks. The complexity of multiple chronic conditions often leads to potentially inappropriate medication use, increasing the risk of adverse drug events, drug-drug interactions, and reduced adherence. This review explores the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, and management strategies for safe deprescribing in multimorbid patients, synthesizing recent advances, guideline recommendations, and practical clinical insights to inform best practices for healthcare professionals.

Introduction

Multimorbidity, defined as the coexistence of two or more chronic conditions in an individual, is increasingly prevalent due to aging populations and advances in medical care. Polypharmacy, or the use of multiple concurrent medications, often follows as clinicians address the various components of multimorbidity. While pharmacotherapy is crucial for disease control, excessive or inappropriate medication use exposes patients to cumulative risks. Safe deprescribing planned and supervised reduction or discontinuation of inappropriate medications emerges as a vital strategy to improve patient outcomes. This article provides a comprehensive review tailored for clinicians on the principles, challenges, and evidence-based approaches to deprescribing in multimorbid populations.

Epidemiology / Disease Burden

The global prevalence of multimorbidity is rising, affecting over half of adults aged 65 and above in developed countries. Polypharmacy is reported in up to 40% of older adults, with one-third of these individuals being prescribed five or more medications. The burden of adverse drug events, hospitalizations, and healthcare costs is disproportionately high in this population. Studies indicate that up to 50% of medications in multimorbid patients may be considered potentially inappropriate, highlighting an urgent need for systematic deprescribing interventions at both primary and specialist care levels.

Pathophysiology

The pathophysiological basis for harm in polypharmacy and multimorbidity is multifactorial. Physiological changes associated with aging and chronic diseases such as altered renal and hepatic function, changes in drug absorption, distribution, and metabolism affect pharmacokinetics and pharmacodynamics. Furthermore, cumulative drug effects and drug-drug interactions may lead to organ system decompensation, cognitive impairment, falls, and frailty. The interplay between chronic diseases and medications can also result in prescribing cascades, wherein side effects of a medication are misinterpreted as new medical conditions, prompting further prescribing rather than deprescribing.

Risk Factors

Risk factors for inappropriate medication use in multimorbid patients include advanced age, cognitive impairment, frailty, multiple prescribers, lack of comprehensive medication review, and transitions of care. Socioeconomic status, limited health literacy, and fragmentation of healthcare services further contribute to polypharmacy risk. Patients with specific conditions such as chronic kidney disease, heart failure, or cognitive disorders are particularly vulnerable to adverse drug events and thus require individualized deprescribing approaches.

Clinical Features

Clinical manifestations of polypharmacy and inappropriate medication use are often subtle and non-specific, including falls, delirium, fatigue, anorexia, and functional decline. These symptoms may be mistakenly attributed to underlying chronic illnesses, underscoring the importance of high clinical suspicion and regular medication review. Additionally, medication-related adverse effects may exacerbate multimorbidity, complicating disease management and reducing adherence to essential therapies.

Diagnosis

Accurate identification of inappropriate medications in multimorbid patients requires a systematic, patient-centered approach. Comprehensive medication review, utilizing tools such as the STOPP/START criteria, Beers Criteria, or Medication Appropriateness Index, is essential. Clinical assessment should include evaluation of current indications, therapeutic goals, risk-benefit analysis, and patient preferences. Collaboration with pharmacists and interdisciplinary teams enhances diagnostic accuracy and safety in deprescribing processes.

Treatment & Management

Safe deprescribing involves a structured process: (1) Identification of potentially inappropriate medications; (2) Assessment of medication necessity, efficacy, and safety; (3) Prioritization based on risk of harm and clinical urgency; (4) Shared decision-making with patients and caregivers; (5) Gradual dose reduction or cessation with close monitoring; and (6) Follow-up to assess withdrawal effects or symptom recurrence. Key principles include continuity of care, patient education, and individualized plans that consider comorbid conditions, life expectancy, and goals of care. Interdisciplinary collaboration and use of electronic health records or clinical decision support tools can facilitate the process.

Recent Advances / Emerging Therapies

Recent evidence supports the use of digital health interventions, artificial intelligence-driven medication review platforms, and pharmacist-led deprescribing initiatives to improve patient safety and outcomes. Ongoing clinical trials are evaluating the impact of deprescribing protocols on quality of life, functional status, and healthcare utilization. Integration of personalized medicine taking into account genomics, pharmacogenomics, and patient-reported outcomes represents a promising avenue for optimizing deprescribing strategies.

Guideline Recommendations

Current guidelines from organizations such as the National Institute for Health and Care Excellence (NICE), American Geriatrics Society, and European Society of Cardiology emphasize routine medication review, application of validated tools, and patient-centered deprescribing. Emphasis is placed on shared decision-making, documentation, and regular reassessment of medication regimens. Guidelines advocate for deprescribing as an ongoing process integrated into chronic disease management, with explicit attention to transitions of care and vulnerable subpopulations.

Conclusion

Safe deprescribing is a cornerstone of high-quality care for patients with multimorbidity, reducing polypharmacy-related harm and enhancing patient outcomes. Clinicians should adopt evidence-based, individualized, and interdisciplinary approaches, supported by guideline recommendations and emerging health technologies. Ongoing research and education in deprescribing are essential to adapt to evolving patient needs and to address the growing burden of multimorbidity in clinical practice.